Bio‑Thera Solutions (SHA: 688177) submitted a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) for Velasitaximab injection (BAT5906), a recombinant humanized anti‑VEGF‑A165 monoclonal antibody, for the treatment of neovascular (wet) age‑related macular degeneration (nAMD).
For Bio‑Thera:NDA submission validates antibody platform beyond biosimilars; VEGF‑A165 selectivity positions for differentiated marketing; potential for global expansion if China data supports US/EU filings.
For Patients:Oral not available; injectable offers alternative to existing anti‑VEGF agents; cost‑effective option could improve access in tier‑2/3 cities.
For Market:First domestic VEGF‑A165 antibody challenges multinational dominance; NRDL negotiation likely in 2026; biosimilar pressure on Eylea/Lucentis creates pricing headroom.
Forward‑Looking Statements This brief contains forward‑looking statements regarding BAT5906’s regulatory review timeline, market penetration, and competitive positioning. Actual results may differ due to NMPA feedback, clinical risks, or competitive responses.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
